Cost-Effectiveness of Generic Semaglutide and SGLT2 Inhibitors in Type 2 Diabetes

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Canadian Journal of Cardiology https://doi.org/10.1016/j.cjca.2026.05.013 
Dr. Ethan McNally  et al.

Points

Exclusivity expiration for semaglutide in Canada in January 2026 enabled generic entry, addressing major cost barriers for patients and provincial drug insurance plans.
Canadian Cardiovascular Society guidelines indicate that between 1.3 million and 2.1 million patients with type 2 diabetes and high cardiorenal risk are eligible for treatment.
Providing brand-name GLP-1RAs to all indicated patients would carry an estimated national annual expenditure between 3.35 billion and 5.31 billion Canadian dollars.
Economic modeling demonstrates that a 60% price reduction makes combined GLP-1RA and SGLT2i therapy the preferred strategy over monotherapies at 50,000 dollars per QALY.
Price reductions of 70% yield a cost-effectiveness ratio of 31,700 dollars per QALY for dual therapy compared to SGLT2i monotherapy alone.

Summary

Health economic cost-effectiveness of generic semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), alone and in combination with sodium-glucose cotransporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes and high cardiorenal risk. Following the regulatory exclusivity expiration for semaglutide in Canada in January 2026, an estimated 1.3 million to 2.1 million patients became eligible for therapy under Canadian Cardiovascular Society guidelines. At pre-generic 2025 prices, providing GLP-1RAs to all indicated patients posed a national drug expenditure of 3.35 billion to 5.31 billion dollars annually.

Investigators utilized a lifetime health economic microsimulation model parameterized with baseline profiles from 216 patients seen at a high-risk cardiorenal clinic to project diabetes complications, healthcare costs in 2023 Canadian dollars, and quality-adjusted life years (QALYs). Guided by a standard willingness-to-pay threshold of 50,000 dollars per QALY, cost-effectiveness was calculated across varying price reductions relative to the Quebec provincial drug plan baseline. Modeling revealed that at a 60% price reduction, complementary combined GLP-1RA and SGLT2i therapy became the preferred clinical management strategy compared to monotherapy or non-SGLT2i standard of care.

At a 70% price reduction, GLP-1RA monotherapy demonstrated favorable cost-effectiveness over non-SGLT2i standard of care with a cost-effectiveness ratio (CER) of 22,700 dollars per QALY. Dual therapy with GLP-1RA and SGLT2i remained more cost-effective than SGLT2i monotherapy with a CER of 31,700 dollars per QALY. These results demonstrate that price reductions driven by generic semaglutide availability render guideline-recommended dual cardiorenal protection cost-effective, supporting expanded public provincial reimbursement regardless of glycemic control targets.

Link to the article: https://onlinecjc.ca/article/S0828-282X(26)00509-X/fulltext

References

McNally, E., Sharma, A., Marques, P., Tsoukas, M. A., Mavrakanas, T. A., & Russell, W. A. (2026). Implications of generic semaglutide availability on the cost-effectiveness of glp-1ra for guideline-indicated patients with type 2 diabetes. Canadian Journal of Cardiology, S0828282X2600509X. https://doi.org/10.1016/j.cjca.2026.05.013